Back to top
more

Swedish Orphan Biovitrum (BIOVF)

(Delayed Data from OTC)

$25.76 USD

25.76
NA

0.00 (0.00%)

Updated May 3, 2024 09:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

All You Need to Know About Swedish Orphan Biovitrum (BIOVF) Rating Upgrade to Strong Buy

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss Estimates

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of -44.44% and 7.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Is Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Swedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 27.27% and 16.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Swedish Orphan Biovitrum (BIOVF) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Medical Stocks Lagging Alcon (ALC) This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Swedish Orphan Biovitrum (BIOVF) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 54.55% and 5.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 237.50% and 2,865.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Swedish Orphan Biovitrum (BIOVF) Beats Q3 Earnings Estimates

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?

by Zacks Equity Research

Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Is Swedish Orphan Biovitrum (BIOVF) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Swedish Orphan Biovitrum (BIOVF) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.

Swedish Orphan Biovitrum (BIOVF)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Is Humana (HUM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Humana (HUM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Has Swedish Orphan Biovitrum (BIOVF) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Swedish Orphan Biovitrum (BIOVF) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.

Swedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Rapt Therapeutics (RAPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -4.55% and 60.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Expected to Decline

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SWEDISH ORP BIO (BIOVF) Earnings Expected to Grow: What to Know Ahead of Q2 Release

by Zacks Equity Research

SWEDISH ORP BIO (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SWEDISH ORP BIO (BIOVF) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

SWEDISH ORP BIO (BIOVF) delivered earnings and revenue surprises of -9.68% and -3.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: SWEDISH ORP BIO (BIOVF) Q1 Earnings Expected to Decline

by Zacks Equity Research

SWEDISH ORP BIO (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.